Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

3.04USD
4:00pm EDT
Price Change (% chg)

$-0.15 (-4.70%)
Prev Close
$3.19
Open
$3.18
Day's High
$3.24
Day's Low
$2.88
Volume
2,159,014
Avg. Vol
251,615
52-wk High
$6.70
52-wk Low
$2.88

SGYP.OQ

Chart for SGYP.OQ

About

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company’s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and... (more)

Overall

Beta: 0.59
Market Cap (Mil.): $302.40
Shares Outstanding (Mil.): 94.80
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 144.28 33.56
EPS (TTM): -0.82 -- --
ROI: -119.82 -2.32 17.36
ROE: -121.29 -6.96 18.23
Search Stocks

Synergy Pharma constipation drug succeeds in trial

- Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout.

30 Apr 2014

UPDATE 2-Synergy Pharma constipation drug succeeds in trial

April 30 - Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout.

30 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks